Navigation Links
Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Date:1/12/2009

BETHESDA, Md., Jan. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases today announced the signing of an option, collaboration and license agreement with Bayer Schering Pharma AG, Germany, under which Bayer Schering Pharma has the exclusive option to obtain a license to one of Micromet's preclinical BiTE antibodies against an undisclosed oncology target.

Under the terms of the agreement, Bayer Schering Pharma will pay Micromet a Euro 4.5 million fee (approx. US$ 6 million) to secure a one year option on a specific BiTE antibody. Bayer Schering Pharma may exercise this option prior to January 5, 2010 through the additional payment of an option exercise fee. The exercise of the option would trigger a formal collaboration between Micromet and Bayer Schering Pharma on the development of the BiTE antibody through the completion of phase 1 clinical trials, at which point Bayer Schering Pharma would assume full control of the further development and commercialization of the BiTE antibody. Micromet would be eligible for an option exercise fee and milestone payments of up to Euro 290 million (approx. US$ 390 million) in total and up to double digit royalties based on tiered net sales of the product. In addition, Micromet would be reimbursed for its R&D expenses incurred in connection with the development of the BiTE antibody in the collaboration with Bayer Schering Pharma.

"We are very pleased with Bayer Schering Pharma's interest in this preclinical BiTE antibody program and their financial commitment to secure exclusive access for the next 12 months. This deal represents further validation of our BiTE antibody technology by a major oncology company," said Christian Itin, Micromet's
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Whitehouse ... officially joined the Morris County (New Jersey) Chamber ... is a leading business organization in the North ... to further engage some key clients in the ... in the geographic area. Membership enables Whitehouse Laboratories ...
(Date:11/26/2014)... Pittsburgh, PA (PRWEB) November 25, 2014 ... release of its official conference and exposition mobile app, ... available for free download in the App Store for ... as a valuable resource tool before, during and after ... guide containing details on exhibiting companies, technical sessions, Conferee ...
(Date:11/26/2014)... 26, 2014 CURE™ magazine ... on December 5, 2014, in San Francisco prior to ... Heroes event will honor clinicians, caregivers, and advocates who ... neoplasms (MPNs). , Special guest speaker Charles Esten, ... cancer journey at the reception. Over a decade ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... a privately-held biotech company using its proprietary platform technology ... gastrointestinal diseases, announced today that it has elected Christopher ... Inc. to its Board of Directors. ... on our Board," said Dr. Barbara Fox, founder, CEO ...
... Inc. (Nasdaq: SGMO ) today announced that the ... Wednesday, May 2, 2012, after the market closes. The press ... p.m. ET, which will be open to the public via ... review the financial results and discuss other business matters. ...
... 2012 The rise of the corporate ... investing are emerging key themes at BioTrinity, the-premier European ... business network which provides comprehensive support for bioscience businesses ... The first day of the conference saw ...
Cached Biology Technology:Avaxia Biologics Elects Christopher Kiritsy to its Board of Directors 2Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 2Corporate Venturing and Early-Stage Financing in the Spotlight at BioTrinity 3
(Date:11/7/2014)... professor, biomedical engineering, in the Grove School of ... have identified a molecule that could lead to ... forms of breast cancer. , Triple negative breast ... to aggressive proliferation and metastasis and a lack ... discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) ...
(Date:11/6/2014)... TALLAHASSEE, Fla. -- A groundbreaking paper from a team ... better understanding of how plants could adapt to and ... The research, published in the latest issue of the ... how chromatin (the complex of DNA and proteins) is ... material, so that some genes are turned on and ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... therapy currently used to treat Helicobacter pylori (H. ... disorders, is unsuccessful in around 25 percent of ... Journal of Gastroenterology, finds that adding a bovine ... yield more effective results, with fewer of the ...
... true spontaneity exist ?in fruit flies. This is what ... 16, 2007 issue of the open-access journal PLoS ONE. ... complex robots which only respond to external stimuli," says ... They are assumed to be input-output devices. "When scientists ...
... but don’t count on them to prevent prostate ... Epidemiology, Biomarkers & Prevention, researchers based at the ... Center report that lycopene, an antioxidant predominately found ... In fact, the researchers noted an association ...
Cached Biology News:Do fruit flies have free will? 2No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2
... provides a convenient method to probe conformational changes ... substrates. Thus, the kit may be used to ... as transport substrates for MDR1. Because UIC2 binding ... substrates, the MDR1 Shift Assay can be utilized ...
... wide and long electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... Zyagen tissue microarrays are derived from Paraffin ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... on coated slides. Sections are large (3-5 ...
... from frozen embedded tissue blocks, which are ... ensure the highest quality. Tissues of each ... sectioned at a thickness of 7microns and ... (3-5mm in diameter) in comparison to core ...
Biology Products: